BOSTON--(BUSINESS WIRE)--Monte Rosa Therapeutics, a biotechnology company focused on developing precision medicines to degrade disease-causing proteins, announced today the appointments of Min Wang, Ph.D., J.D., as Chief Operating Officer, Ajim Tamboli, CFA, as Chief Financial Officer and Jullian G. Jones, Ph.D., J.D., MBA, as Senior Vice President, Head of Business Development.
“We are thrilled to welcome Min, Ajim and Jullian to our executive leadership team. With the recent closing of our $96 million Series B financing, they will each play key roles in Monte Rosa’s future success as we identify our first development candidates and continue to bolster our molecular glue platform,” said Monte Rosa CEO Markus Warmuth, M.D. “Min’s 20-plus years of senior leadership, business and legal experience in the pharmaceutical and biotech industry will position Monte Rosa for growth and operational excellence. Similarly, Ajim brings more than two decades of experience in life sciences investing and banking to Monte Rosa. Finally, Jullian’s broad corporate strategy and business development expertise will be invaluable to Monte Rosa as we move toward our goal of eradicating undruggable proteins that cause or drive the progression of genomically defined diseases intractable to standard care.”
Prior to joining Monte Rosa, Dr. Wang served as COO of BlueRock Therapeutics, where she played a key role in shaping its strategy and operations, including the sale of the company for an implied total value of up to $1 billion. She previously served as Senior Vice President, General Counsel at Agios from inception through its IPO to a fully integrated biopharmaceutical company. During her tenure, Agios received two product approvals from the FDA, raised $1.5 billion in public market funding, and executed numerous co-development and co-commercialization deals with industry partners. Before Agios, Dr. Wang served as Senior Patent Counsel at Genentech and Merck, where she managed a wide range of therapeutic portfolios. Dr. Wang received her Ph.D. in organic chemistry from Brown University and her J.D. from Fordham University School of Law.
Mr. Tamboli joins Monte Rosa from Rodin Therapeutics, where he served as CFO and was integral in the sale of the company to Alkermes for consideration in aggregate value of up to $950 million. He was previously focused on life sciences investing and managed a global portfolio of biotech and pharmaceutical companies, notably as a founding partner of Endurant Capital Management and with Columbia Management. Earlier in his career, Mr. Tamboli led coverage of and executed IPOs and follow-on offerings for numerous biotech and healthcare companies at Lehman Brothers, Credit Suisse and Lazard Frères. Mr. Tamboli received his M.S. in molecular biology and B.S. in biomedical science from the University of Pennsylvania, where he was a Benjamin Franklin Scholar. He is a CFA® charterholder.
Before joining Monte Rosa, Dr. Jones served as Senior Director of Oncology Business Development at Eli Lilly and Company, where she led the identification and strategic assessment of in-licensing and M&A oncology opportunities across the clinical and preclinical portfolio, as well as out-licensing activities. Dr. Jones was pivotal in leading several oncology M&A activities at Lilly, including the $8 billion acquisition of Loxo Oncology. Prior to Lilly, Dr. Jones served in several leadership roles at Boehringer Ingelheim, including business development and licensing, marketing and new product planning. Dr. Jones began her life sciences business development career at Columbia Technology Ventures (CTV). At CTV, she was also responsible for facilitating the spin-off of early-phase companies. Dr. Jones has a Ph.D. from Johns Hopkins University, a J.D. from Georgetown Law Center and an MBA from Columbia University.
About Monte Rosa
Monte Rosa Therapeutics is a biotechnology company developing molecular glues to degrade disease-causing proteins. The company has created a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland. For more information, visit www.monterosatx.com.